April 19, 2018 04:42 AM EDTUpdated 05:04 AM
People
R&D

No­var­tis poach­es Bris­tol-My­ers/Am­gen vet John Tsai for top drug de­vel­op­ment post in a $9B or­ga­ni­za­tion

John Carroll

Editor & Founder

No­var­tis CEO Vas Narasimhan has found his re­place­ment as head of their glob­al drug de­vel­op­ment or­ga­ni­za­tion at Am­gen, a big phar­ma part­ner which has led …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times